A

AIM Trials, LLC | Plano, TX

Research site
(Unclaimed)
Location
6404 International Parkway, Suite 1010, Plano, Texas, United States of America
Site insights

Top conditions

Migraine Disorders (3 trials)

Irritable Bowel Syndrome (2 trials)

Depression (2 trials)

Syndrome (2 trials)

Depressive Disorder (2 trials)

Top treatments

Vortioxetine
Tenapanor
Androderm
Fluoxetine
Ziprasidone
Allopurinol
EYE103
Eptinezumab
Pimavanserin
Iclepertin

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

10 of 19
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...

Enrolling
Diabetic Macular Edema (DME)
Neovascular Age-related Macular Degeneration (NVAMD)
Drug: EYE103
Locations recently updated

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Enrolling
COVID-19
Influenza
Biological: Placebo
Biological: Influenza and COVID-19 Combination B

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Enrolling
Schizophrenia
Drug: Placebo
Drug: Iclepertin

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

6-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group study in children and adolescents (aged 5 to17 years) with autism sp...

Enrolling
Irritability Associated With Autism Spectrum Disorder
Drug: Pimavanserin
Drug: Placebo

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

Invitation-only
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor

This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediat...

Enrolling
Irritable Bowel Syndrome With Constipation (IBS-C)
Drug: Tenapanor 50 MG
Drug: Placebo

The aim of this 12-month randomized multi-regional double-blind parallel group allopurinol and placebo-controlled phase 3 study is to assess the effi...

Enrolling
Hyperuricemia
Tophi
Drug: Tigulixostat
Drug: Placebo

Trial sponsors

Pfizer logo

Pfizer (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems